Comparison of rivaroxaban doses: 2.5 mg, 15 mg, and 20 mg. When, for whom, and which dose? Review article

Article Sidebar

Requires Subscription PDF (Język Polski)


Published: Oct 20, 2026
DOI: https://doi.org/10.24292/01.MF.0226.3
Keywords:
rivaroxaban, atrial fibrillation, ROCKET AF, COMPASS, intracranial hemorrhage, MALE, anticoagulation, primary care

Main Article Content

Paweł Balsam
I Katedra i Klinika Kardiologii, Warszawski Uniwersytet Medyczny

Abstract

Rivaroxaban is one of the most commonly used direct oral anticoagulants in everyday clinical practice. It is available in several doses with distinct therapeutic indications: full-dose anticoagulation in patients with atrial fibrillation (20 mg or 15 mg once daily) and secondary vascular prevention in patients with chronic coronary syndromes or symptomatic peripheral artery disease (2.5 mg twice daily in combination with acetylsalicylic acid). Differences in dosing regimens may lead to uncertainty and therapeutic errors. The aim of this article is to provide a comprehensive overview of the principles of rivaroxaban dose selection in primary care, with reference to the pivotal ROCKET AF and COMPASS trials, as well as practical aspects of once- versus twice-daily dosing, treatment adherence, bleeding safety, and appropriate patient selection.

Article Details

How to Cite
Balsam, P. (2026). Comparison of rivaroxaban doses: 2.5 mg, 15 mg, and 20 mg. When, for whom, and which dose?. Medycyna Faktow (J EBM), 19(2(71), 161-165. https://doi.org/10.24292/01.MF.0226.3
Issue
Vol 19 No 2(71) (2026)
Section
Articles

Copyright by Medical Education. All rights reserved.

References

1. Mazzolai L, Teixido-Tura G, Lanzi S et al. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024; 45(36): 3538-700. http://doi.org/10.1093/eurheartj/ehae179.
2. Van Gelder IC, Rienstra M, Bunting KV et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024; 45(36): 3314-414. http://doi.org/10.1093/eurheartj/ehae176.
3. Vrints C, Andreotti F, Koskinas KC et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024; 45(36): 3415-537. http://doi.org/10.1093/eurheartj/ehae177.
4. European Medicines Agency (EMA). Xarelto.
5. Steffel J, Collins R, Antz M et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021; 23(10): 1612-76. http://doi.org/10.1093/europace/euab065.
6. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10): 883-91. http://doi.org/10.1056/NEJMoa1009638.
7. Eikelboom JW, Connolly SJ, Bosch J et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017; 377(14): 1319-30. http://doi.org/10.1056/NEJMoa1709118.
8. Fox KAA, Eikelboom JW, Shestakovska O et al. Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial. J Am Coll Cardiol. 2019; 73(18): 2243-50. http://doi.org/10.1016/j.jacc.2019.02.048.
9. Sharma M, Hart RG, Connolly SJ et al. Stroke Outcomes in the COMPASS Trial. Circulation. 2019; 139(9): 1134-45. http://doi.org/10.1161/CIRCULATIONAHA.118.035864.
10. Anand SS, Caron F, Eikelboom JW et al. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial. J Am Coll Cardiol. 2018; 71(20): 2306-15. http://doi.org/10.1016/j.jacc.2018.03.008 11. Branch KRH, Probstfield JL, Bosch J et al. Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: The COMPASS trial. Am Heart J. 2023; 258: 60-8. http://doi.org/10.1016/j.ahj.2023.01.008.